SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001062993-23-023281
Filing Date
2023-12-29
Accepted
2023-12-29 16:30:47
Documents
81
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 20-F form20f.htm   iXBRL 20-F 1980473
2 EXHIBIT 2.1 exhibit2-1.htm EX-2.1 692
3 EXHIBIT 2.2 exhibit2-2.htm EX-2.2 6994
4 EXHIBIT 8.1 exhibit8-1.htm EX-8.1 1062
5 EXHIBIT 12.1 exhibit12-1.htm EX-12.1 7773
6 EXHIBIT 12.2 exhibit12-2.htm EX-12.2 7781
7 EXHIBIT 13.1 exhibit13-1.htm EX-13.1 6666
8 EXHIBIT 16.1 exhibit16-1.htm EX-16.1 22786
9 EXHIBIT 97.1 exhibit97-1.htm EX-97.1 47244
15 GRAPHIC exhibit2-1xu002.jpg GRAPHIC 88424
16 GRAPHIC exhibit2-1xu003.jpg GRAPHIC 212848
17 GRAPHIC exhibit16-1xu001.jpg GRAPHIC 10071
18 GRAPHIC form20fxz001.jpg GRAPHIC 52493
19 GRAPHIC form20fxz002.jpg GRAPHIC 39963
20 GRAPHIC form20fxz003.jpg GRAPHIC 19499
21 GRAPHIC form20fxz004.jpg GRAPHIC 14285
  Complete submission text file 0001062993-23-023281.txt   9140120

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT drug-20230930.xsd EX-101.SCH 117909
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT drug-20230930_cal.xml EX-101.CAL 33327
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT drug-20230930_def.xml EX-101.DEF 257922
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT drug-20230930_lab.xml EX-101.LAB 1002945
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT drug-20230930_pre.xml EX-101.PRE 387423
75 EXTRACTED XBRL INSTANCE DOCUMENT form20f_htm.xml XML 1192274
Mailing Address 19 VESTRY STREET NEW YORK NY 10013
Business Address 19 VESTRY STREET NEW YORK NY 10013 6474072515
BRIGHT MINDS BIOSCIENCES INC. (Filer) CIK: 0001827401 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 20-F | Act: 34 | File No.: 001-40997 | Film No.: 231528097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)